Key result
Epithelial Protein Lost In Neoplasm (EPLIN) plays a key role in the progression and metastasis of certain solid tumours, with expanding roles in cell cycle, gene regulation, and lipid metabolism.
Why the study?
Recent years have seen rapid progress in understanding the cellular, molecular, and clinical mechanisms of EPLIN across cancers and biological processes, expanding beyond its initial characterization.
This review summarizes the expanding biological roles of EPLIN, particularly its mechanisms in cancer progression and metastasis.
EPLIN may guide future oncology therapies; leaves open validation in prospective trials.
Epithelial Protein Lost In Neoplasm (EPLIN), also known as LIMA1 (LIM Domain And Actin Binding 1), was first discovered as a protein differentially expressed in normal and cancerous cell lines. It is now known to be key to the progression and metastasis of certain solid tumours. Despite a slow pace in understanding the biological role in cells and body systems, as well as its clinical implications in the early years since its discovery, recent years have witnessed a rapid progress in understanding the mechanisms of this protein in cells, diseases and indeed the body. EPLIN has drawn more attention over the past few years with its roles expanding from cell migration and cytoskeletal dynamics, to cell cycle, gene regulation, angiogenesis/lymphangiogenesis and lipid metabolism. This concise review summarises and discusses the recent progress in understanding EPLIN in biological processes and its implications in cancer.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2021) conducted a review in Cancer. Epithelial Protein Lost In Neoplasm (EPLIN) was evaluated. Epithelial Protein Lost In Neoplasm (EPLIN) plays a key role in the progression and metastasis of certain solid tumours, with expanding roles in cell cycle, gene regulation, and lipid metabolism.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: